Treatment of Polydrug-Using Opiate Dependents During Withdrawal
|ClinicalTrials.gov Identifier: NCT00367874|
Recruitment Status : Completed
First Posted : August 23, 2006
Last Update Posted : August 23, 2006
Managed detoxification is a first and necessary step prior to treatment and rehabilitation. Detoxification can be a major obstacle for some patients, and the availability of managed and safe withdrawal is a prerequisite for long-term treatment.
In our clinical practice we have felt the need for a standardised and safe detoxification treatment regimen for our opioid addicts, as dependence on multiple drugs is so common.
- To assess whether a novel standardised treatment regimen - Buprenorphine (BPN) combined with Valproate (VPA) - will result in fewer withdrawal symptoms during detoxification of opiate–polydrug users than the existing treatment regimen, i.e. Clonidine (CLN) combined with Carbamazepine (CBZ).
- To determine whether there are differences in treatment retention between the BPN/VPA and the CLN/CBZ groups.
- To assess differences in clinical side-effects and biochemical interactions between the two treatment regimens.
|Condition or disease||Intervention/treatment||Phase|
|Opiate Dependence Drug Dependence Substance Withdrawal Syndrome||Drug: Buprenorphine Drug: Valproate||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||12 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Treatment of Polydrug-Using Opiate Dependents During Withdrawal|
|Study Start Date :||February 2003|
|Study Completion Date :||November 2003|
- Retention in treatment
- Withdrawal symptoms
- Serum concentration of Valproate and Buprenorphine separately and in combination
- Urine testing
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00367874
|Sorlandet Hospital HF, Addiction Unit (ARA)|
|Kristiansand, Vest-Agder, Norway, N-4604|
|Principal Investigator:||Oistein Kristensen, MD||Sorlandet Hospital HF, Addiction Unit|